John Maraganore Biography and Net Worth

Since 2002, Dr. John Maraganore has served as the CEO and a Director of Alnylam.

Prior to Alnylam, Dr. Maraganore served as an officer and a member of the management team for Millennium Pharmaceuticals, Inc. As Senior Vice President, Strategic Product Development for Millennium, he was responsible for the company’s product franchises in oncology, and cardiovascular, inflammatory, and metabolic diseases. He was previously Vice President, Strategic Planning and M&A and, prior to that, he was General Manager of Millennium BioTherapeutics, Inc., a former subsidiary of Millennium. Before Millennium he served as Director of Molecular Biology and Director of Market and Business Development at Biogen, Inc. At Biogen, Dr. Maraganore invented and led the discovery and development of ANGIOMAX® (bivalirudin) for injection, formerly HIRULOGTM and currently marketed by The Medicines Company. Prior to Biogen, Dr. Maraganore was a scientist at ZymoGenetics, Inc., and the Upjohn Company.

Dr. Maraganore received his Master of Science and Ph.D. in biochemistry and molecular biology at the University of Chicago. He is a member of the Board for Agios Pharmaceuticals and Biotechnology Industry Organization (BIO) Board and is a member of the BIO Executive Committee.

What is John Maraganore's net worth?: The estimated net worth of John Maraganore is at least $62.14 million as of August 13th, 2021. Dr. Maraganore owns 248,744 shares of Alnylam Pharmaceuticals stock worth more than $62,138,739 as of November 21st. This net worth estimate does not reflect any other investments that Dr. Maraganore may own. Learn More about John Maraganore's net worth.
How do I contact John Maraganore?: The corporate mailing address for Dr. Maraganore and other Alnylam Pharmaceuticals executives is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. Alnylam Pharmaceuticals can also be reached via phone at (617) 551-8200 and via email at [email protected]. Learn More on John Maraganore's contact information.
Has John Maraganore been buying or selling shares of Alnylam Pharmaceuticals?: John Maraganore has not been actively trading shares of Alnylam Pharmaceuticals during the last ninety days. Most recently, John Maraganore sold 33,978 shares of the business's stock in a transaction on Friday, November 12th. The shares were sold at an average price of $171.52, for a transaction totalling $5,827,906.56. Learn More on John Maraganore's trading history.
Who are Alnylam Pharmaceuticals' active insiders?: Alnylam Pharmaceuticals' insider roster includes Dennis Ausiello (Director), Michael Bonney (Director), Jeffrey Dunn (CEO), Kevin Fitzgerald (EVP), Indrani Franchini (EVP), Pushkal Garg (CMO), Yvonne Greenstreet (COO), Laurie Keating (EVP), John Maraganore (CEO), Steven Paul (Director), Jeffrey Poulton (CFO), David Pyott (Director), Amy Schulman (Director), Phillip Sharp (Director), Tolga Tanguler (EVP), and Akshay Vaishnaw (Insider). Learn More on Alnylam Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Alnylam Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 11 times. They sold a total of 154,848 shares worth more than $34,733,444.48. The most recent insider tranaction occured on August, 20th when CEO Yvonne Greenstreet sold 15,000 shares worth more than $4,200,000.00. Insiders at Alnylam Pharmaceuticals own 1.5% of the company. Learn More about insider trades at Alnylam Pharmaceuticals.
Information on this page was last updated on 8/20/2024.

John Maraganore Insider Trading History at Alnylam Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/12/2021	Sell	33,978	$171.52	$5,827,906.56
8/13/2021	Sell	33,979	$199.78	$6,788,324.62	248,744
5/13/2021	Sell	33,979	$130.78	$4,443,773.62	248,744
8/20/2020	Sell	34,765	$136.13	$4,732,559.45
5/20/2020	Sell	34,765	$143.22	$4,979,043.30	232,354
2/20/2020	Sell	34,765	$131.85	$4,583,765.25	224,758
10/14/2019	Sell	49,456	$79.45	$3,929,279.20	239,449
5/15/2019	Sell	49,457	$70.00	$3,461,990.00	239,450
7/25/2018	Sell	50,000	$105.39	$5,269,500.00	201,297
11/22/2017	Sell	73,415	$130.90	$9,610,023.50	223,125
11/15/2017	Sell	74,000	$126.86	$9,387,640.00	223,710
7/20/2016	Sell	30,151	$64.69	$1,950,468.19	148,465
4/20/2016	Sell	30,151	$67.46	$2,033,986.46	148,465
1/20/2016	Sell	30,152	$71.78	$2,164,310.56	133,389
12/2/2015	Sell	58,689	$104.87	$6,154,715.43	133,389
11/20/2015	Sell	58,690	$102.88	$6,038,027.20	133,389
1/26/2015	Buy	10,000	$95.00	$950,000.00
9/18/2014	Sell	113,668	$77.71	$8,833,140.28
6/26/2014	Sell	113,668	$65.45	$7,439,570.60
5/15/2014	Sell	113,668	$56.73	$6,448,385.64	106,320
9/11/2013	Sell	58,947	$55.50	$3,271,558.50
8/14/2013	Sell	60,000	$48.97	$2,938,200.00	18,617
7/10/2013	Sell	60,000	$37.11	$2,226,600.00

John Maraganore Buying and Selling Activity at Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Company Overview

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $249.81

$246.64

$250.68

50 Day Range

MA: $273.83

$232.27

$300.55

2 Week Range

Now: $249.81

$141.98

$304.39

Volume

219,706 shs

Average Volume

876,170 shs

Market Capitalization

$32.22 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.39

Trump’s Sending THIS Crypto Higher on Purpose

From Crypto 101 Media | Ad

Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…

YES, I WANT THE #1 CRYPTO NOW